AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 41 min read$ALEC

Rosenthal Arnon sold $193K of ALEC

Rosenthal Arnon (Chief Executive Officer) sold 72,606 shares of Alector, Inc. (ALEC) at $2.66 ($0.19M total) on 2026-09-03.

Original reporting
SEC EDGAR · Rosenthal Arnon
Published Sep 4, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALEC
Bearish
medium confidence
Mentioned
$ALEC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECBearishLow
01

Why it matters

A modest insider sell may cause short-term price softness but is unlikely to drive major moves.

02

Market read

Provides fresh data for traders monitoring insider activity; may influence short-term trading decisions.

03

What to watch

Arnon's holdings remain large (over 2.2 million shares), indicating continued commitment.

Relevance 4/10Novelty 4/10Timing: post-market filing on 2026-09-04

Background

Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$ALECBearishMedium confidence
Context

CEO Rosenthal Arnon sold 72,606 shares for $193,473, reducing his stake.

Expected impact

Modest downside pressure in the near term.

Evidence & confidence

A $193k sale by the CEO is modest but notable; markets often react negatively to insider sells.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector-wide.

Regional

No significant regional effect.

Global

Limited to investors tracking Alector.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a lack of confidence.

Key entities

  • Company
    Alector, Inc.

    Biotech firm listed on NASDAQ under ticker ALEC.

  • Person
    Rosenthal Arnon

    Chief Executive Officer of Alector.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALEC insider trading history →

Related articles

AUG 6
$ALECMed

Alector, Inc. (ALEC): Results of Operations and Financial Condition

Alector, Inc. (ALEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ)

SEC EDGAR 8-K6 min
JUN 8
$ALECMedAI 8/10

UAE Business: ALEC unit Target wins $500m three EPC contracts in Gulf

ALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.

gdnonline.com3 min